TERANODE AWARDED PATENT ENABLES ADAPTIVE WORKFLOW
Unique Informatics Technology Improves Workflow Flexibility and Data Integration
Seattle, WA – May 1, 2006 – Teranode Corporation, the leading innovator of scientific data and workflow management software for the Life Sciences industry, today announced the U.S. Patent and Trademark Office (PTO) has issued the company U.S. Patent No. 7,010,760 B2 for a key element of TERANODE XDA. The patent protects the method and apparatus for TERANODE XDA's match rules, a feature for integrating datasets and metadata in dynamic workflow. By automating critical data integration, the match rules enable scientists to quickly and reliably understand the provenance and relationships of data within projects.
Traditional informatics solutions depend on static, predefined schemas and workflows which are brittle and often break down when scientists need to make changes to the design of an experiment. TERANODE XDA accommodates change through an adaptive schema and workflow capability without requiring error-prone, manual data management procedures or expensive reprogramming.
"TERANODE XDA is the first product to integrate process metadata, schema metadata, and instrument data as part of a workflow," said Larry Arnstein, CTO of Teranode. "The match rules technology provides new flexibility in laboratory operations, while providing unrivaled data integration. Once captured, TERANODE XDA leverages semantic web standards to unlock the true potential of the data by enabling analysis, reporting, and search across projects and disciplines."
TERANODE XDA is a powerful informatics platform that leverages existing IT infrastructure to manage scientific data and workflow. TERANODE XDA allows scientists to automate workflow, manage the lifecycle of scientific data, and unify disparate data across laboratories, improving the speed and quality of R&D projects.
About Teranode Corporation
Teranode Corporation, a venture-backed company headquartered in Seattle, Washington, is the leading innovator of scientific data and workflow management software for the Life Sciences industry. Teranode's award-winning products are used by leading pharmaceutical, biotechnology, research, and academic organizations, including Pfizer, AstraZeneca, NIH Chemical Genomics Center, MIT, and Fred Hutchinson Cancer Research Center, to improve the speed and value of experimentation in R&D and then share chemical and biological knowledge enterprise-wide. For more information, visit www.teranode.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
